Abstract: Disclosed are compounds of formula (I) as follows: in which each of R1, R2, R3, R4, R5, L1, W, and Het is defined herein. Also provides are a method of inhibiting prostaglandin reductase 2 (“PTGR2”) using such a compound and a pharmaceutical composition containing same.

Abstract: Disclosed are compounds of formula (I) as follows: in which each of R1, R2, R3, R4, R5, L1, W, and Het is defined herein. Also provides are a method of inhibiting prostaglandin reductase 2 (“PTGR2”) using such a compound and a pharmaceutical composition containing same.

Abstract: The present invention generally is related to a method for increasing the content of the non-digestible cereal foodstuffs for applying to the people acquired of metabolic syndromes. The method according to the present invention mainly includes a feed preparation step in which the ingredients are ground into powders and then screened by 80 to 100 meshes. Then, a press-kneading step is used to heat up and to press kneading the ingredients in sequence. The semi-finished products made in the second step is delivered to the output of the line, cooperating with a die and a blade, is conducted to form in a press-forming step. The formed pre-product is dried by an intermittent heating method in the drying step. Then, a binder is added to and sufficiently mixed with the semi-finished products to form a film coat on the surface of the pre-product and then is dried in a film-coat forming step.

Abstract: Provided are methods of identifying Metabolic Syndrome phenotypes for an organism or a biological sample derived therefrom which methods are based on detecting a polymorphism, haplotype, haplotype group, or haplotype subgroup in the mitochondrial genome of the organism and correlating the polymorphism or haplotype to a Metabolic Syndrome phenotype. Also provided are systems or kits for the detection of such polymorphisms or haplotypes and the correlation of the polymorphisms or haplotypes to a Metabolic Syndrome phenotype. Provided are methods of identifying a modulator of a Metabolic Syndrome phenotype and kits for the treatment of a Metabolic Syndrome phenotype.

Abstract: The present invention provides methods, compositions, and kits useful for modulating insulin/glucose homeostasis in a subject by modulating CAP/SORBS1. In addition, the invention provides a variety of prescreening and screening methods aimed at identifying agents that modulate insulin/glucose homeostasis. Methods of the invention can involve assaying test agent binding to CAP/SORBS1 polypeptides or polynucleotides. Alternatively, test agents can be screened for their ability to alter the level of CAP/SORBS1 polypeptides, polynucleotides, or action.

Abstract: Recent data indicate that a loss-of-function mutation of the SLC2A10 gene causes arterial tortuosity syndrome (ATS) via upregulation of the TGF-? pathway in the arterial wall, a mechanism possibly causing vascular changes associated with diabetes. It is determined that SLC2A10 (Solute carrier family 2, facilitated glucose transporter, member 10) genetic polymorphism is associated with peripheral vascular disease (PVD) in patients with type 2 diabetes.

Abstract: An isolated polypeptide containing the sequence of SEQ ID NO:1 or a functional equivalent of SEQ ID NO:1, in which the polypeptide reduces 15-keto prostaglandin but not leukotriene B4. Also disclosed is an antibody that binds specifically to the polypeptide and a double-stranded ribonucleic acid for inhibiting expression of the 15-keto prostaglandin-?13-reductase.

Abstract: A method of treating a peroxisome proliferators-activated receptors related disease by administering to a subject in need thereof an effective amount of a modulator of 15-keto prostaglandin-?13-reductase. Also disclosed are methods of identifying a compound for inhibiting activity of the reductase and of lowering blood glucose levels by administering to a subject an effective amount of a reductase inhibitor.

Abstract: A method of treating a peroxisome proliferators-activated receptors related disease by administering to a subject in need thereof an effective amount of a modulator of 15-keto prostaglandin-?13-reductase. Also disclosed are methods of identifying a compound for inhibiting activity of the reductase and of lowering blood glucose levels by administering to a subject an effective amount of a reductase inhibitor.

Abstract: An isolated polypeptide containing the sequence of SEQ ID NO: 1 or a functional equivalent of SEQ ID NO:1, in which the polypeptide reduces 15-keto prostaglandin but not leukotriene B4. Also disclosed is an antibody that binds specifically to the polypeptide and a double-stranded ribonucleic acid for inhibiting expression of the 15-keto prostaglandin-?13-reductase.

Abstract: The present invention identifies mutations in the human sorbin and SH3-domain-containing-1 (SORBS1) gene, particularly at one or more of positions 220; 249; −7 with respect to exon 5; −25 with respect to exon 6; 682; +64 with respect to exon 9; +61 with respect to exon 10; +69 with respect to exon 11; +33 with respect to exon 16; 1482; 1518; −6 with respect to exon 22; +79 with respect to exon 24; and 2337. A polymorphism at position 682 within exon 7, the T228A allele, correlates with the phenotypes of low blood pressure and low body mass index, and is a protective marker for obesity, diabetes, and hypertension. The invention also relates to methods and materials for detecting single nucleotide polymorphisms in the SORBS1 gene and to the use of SORBS1 polymorphisms in the diagnosis, screening, and treatment of type 2 diabetes, obesity, hypertension, atherosclerosis, and metabolic syndrome.